Health
Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder
- ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now commercially available in the U.S. -- Ann & Robert H. Lurie Children's Hospital of Chicago, a top-ranked hospital, is ready to evaluate patients for ZEVASKYN treatment -- Abeona Assist™ comprehensive patient services program in place to offer personalized support for eligible patients and their families throughout ZEVASKYN treatment journey -CLEVELAND and CHICAGO, May 1
About this update from Abeona Therapeutics Inc.
[{"type":"image","alt":"Abeona Therapeutics Inc.","displaySize":"","headline":null,"caption":"Abeona Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":256,"height":181,"url":"https://media.zenfs.com/en/globenewswire.com/29420b6ac7ca8949eb7c2a775811595d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qj_IDTqo2_8aVBxsha_Qwg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI5NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/29420b6ac7ca8949eb7c2a775811595d","width":256,"height":181}},"lazy":false},{"type":"text","content":"- ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now commercially available in the U.S. -","length":164,"tagName":"p"},{"type":"text","content":"- Ann & Robert H. Lurie Children's Hospital of Chicago, a top-ranked hospital, is ready to evaluate patients for ZEVASKYN treatment -","length":141,"tagName":"p"},{"type":"text","content":"- Abeona Assist™ comprehensive patient services program in place to offer personalized support for eligible patients and their families throughout ZEVASKYN treatment journey -","length":175,"tagName":"p"},{"type":"text","content":"CLEVELAND and CHICAGO, May 14, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) and Ann & Robert H. Lurie Children’s Hospital of Chicago today announced that Lurie Children’s is now activated as the first Qualified Treatment Center (QTC) for ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. This groundbreaking therapy will be used to treat wounds associated with recessive dystrophic epidermolysis bullosa (RDEB) – a rare skin disorder characterized by severe, painful wounds that can lead to systemic complications impacting the length and quality of life. Lurie Children’s has completed QTC start-up activities enabling it to begin patient identification for scheduling of ZEVASKYN treatment. Treatments are expected to begin in the third quarter of 2025.","length":795,"tagName":"p"},{"type":"text","content":"On April 29, 2025, Abeona announced approval from the U.S. Food and Drug Administration (FDA) for ZEVASKYN as the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with RDEB. There is no cure for RDEB and ZEVASKYN is the only FDA-approved product to treat RDEB wounds wit...